Juvisync FDA Approval History
FDA Approved: Yes (Discontinued) (First approved October 7, 2011)
Brand name: Juvisync
Generic name: simvastatin and sitagliptin
Dosage form: Tablets
Company: Merck
Treatment for: Diabetes, Type 2, High Cholesterol, Familial Homozygous, High Cholesterol, Familial Heterozygous, Hypertriglyceridemia
Marketing Status: Discontinued
Juvisync (simvastatin and sitagliptin) is an HMG-CoA reductase inhibitor (statin) and dipeptidyl peptidase-4 (DPP-4) inhibitor fixed dose combination for the treatment of high cholesterol and type 2 diabetes.
Development timeline for Juvisync
| Date | Article |
|---|---|
| Oct 7, 2011 | Approval FDA Approves Combination Therapy Juvisync |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.